Quantcast

Challenges and Opportunities: in the Renal Denervation Market

October 17, 2013

Reportbuyer.com just published a new market research report: Challenges and Opportunities: in the Renal Denervation Market.

London (PRWEB) October 17, 2013

Hypertension: Prevalence and Significance

Hypertension is one of the most preventable causes of premature morbidity and mortality globally. It is a major risk factor for stroke, myocardial infarction, heart failure, chronic kidney disease, peripheral vascular disease, cognitive decline, damage to retinal blood vessels and visual impairment, and premature death. Therefore, reducing hypertension is a factor in lowering the incidence of these conditions, helping to improve the health of the population and reducing the high burdens that they place on global healthcare systems.

Renal denervation therapy involves a surgical procedure and is therefore a last resort in the treatment of hypertension. It is only considered when cheaper, simpler and potentially safer alternatives such as lifestyle modifications and the use of pharmaceuticals have failed. These patients are termed as having treatment-resistant hypertension.

Current Trends and Future Opportunities

With renal denervation technology only having been in development since the late 1990s and commercially-available since 2010, the market is in its infancy. The products remain unapproved in the US and Japan, and reimbursement is not yet widely available in other regions. Despite being an emerging market, renal denervation has sparked considerable interest due to the good safety and efficacy results it has achieved so far in helping to reduce treatment-resistant hypertension. The expectation is that renal denervation could become a multi-billion dollar market in the future.

Understand the current trends and future opportunities to invest in, in this essential report, and learn about the products and technologies leading this dynamic market. Challenges and Opportunities in the Renal Denervation Market is the complete guide with all you need to know!

What does this critical business analysis resource provide?

•A detailed understanding of the situation relating to treatment-resistant hypertension and the role of renal denervation

•A thorough understanding of the competitive landscape

•Current trends and future opportunities – reviews of the US and Japan new market access and market prospects

•Understand the benefits and disadvantages of major renal denervation techniques

•In-depth reviews of the products and technologies leading the market – including products currently available and in development

•Company directory – including detailed company profiles – learn who your competitors are and their current market position.

Who is this report for?

Challenges & Opportunities in the Renal Denervation Market is the ideal companion in today's dynamic renal denervation market environment. The need to understand key changes in the marketplace, and be able to quickly answer those questions that arise daily, is essential. That is why this current and comprehensive review of the trends, products and competitive landscape is an invaluable aid for every cardiovascular industry executive.

EXECUTIVE SUMMARY 1

INTRODUCTION 2

Hypertension: Prevalence and Significance 2

Treatment-Resistant Hypertension and the Role of Renal Denervation 3

COMPETITIVE LANDSCAPE 4

Fig.1: Renal Denervation Market Shares by Competitor, 2012 5

CURRENT TRENDS AND FUTURE OPPORTUNITIES 6

Renal Denervation Market, 2011-2012 (US$ millions) 6

Fig.2: Renal Denervation Market by Region, 2012 6

Regional Perspective and Reimbursement 7

The US and Japan: Access to New Markets 7

Gaining Clinical and Cost-Effectiveness Evidence 7

Cost-Effectiveness Analysis 8

Addressable Market: Resistant Hypertension Prevalence and Patient Selection Criteria 8

Currently-Eligible Patients for Renal Denervation 9

Current Renal Denervation Market Opportunity, Global and US 9

Expanding Clinical Indications 10

Heart Failure and Renal Impairment 10

HF Clinical Studies 11

Rival Technologies for Treatment-Resistant Hypertension 11

Summary: Market Drivers, Restraints and Opportunities 12

MARKET PROSPECTS 13

Fig.3: Renal Denervation Market, 2011-2017E (US$ billion) 14

Fig.4: Renal Denervation Market Growth, 2012-2017E (%) 14

Products and technologies 15

RENAL DENERVATION TECHNIQUES 15

Major Renal Denervation Techniques: Benefits & Disadvantages 16

PRODUCTS AVAILABLE OR IN DEVELOPMENT 17

CURRENTLY-AVAILABLE PRODUCTS 17

Medtronic’s Symplicity Renal Denervation System 17

Symplicity Clinical Trials 18

Symplicity HTN-1 18

Symplicity HTN-2 18

Symplicity HTN-3 19

Symplicity HTN-4 19

Symplicity HTN-Japan 19

Global SYMPLICITY Patient Registry 20

SYMPLICITY-HF 20

Symplicity Health-Economic Analysis 20

St Jude Medical’s EnligHTN 21

EnligHTN Clinical Studies 21

EnligHTNment Clinical Trial 22

ReCor Medical’s PARADISE Systems 22

Clinical Studies 22

Covidien’s OneShot Renal Denervation Device 23

Boston Scientific’s Vessix Vascular V2 Renal Denervation System 23

Clinical Trials 24

Shanghai AngioCare Medical Technology’s Iberis Renal Sympathetic Denervation System 24

PRODUCTS IN DEVELOPMENT 25

In Clinical Development 25

Medtronic’s Symplicity Spyral Multi-Electrode RF Renal Denervation System 25

Feasibility Study Results 25

Sound Interventions’ Circumferential Therapeutic Ultrasound Technology 25

Pre-Clinical Studies 26

SOUND-ITV Clinical Study 26

Kona Medical’s Surround Sound 26

WAVE I Study Results 27

St Jude Medical’s Second-Generation EnligHTN System 27

Johnson & Johnson (Cordis)’s Renal Denervation Projects 27

Renal Denervation with the Celsius Thermacool Ablation Catheter 27

RELIEF Clinical Study 28

Celsius ThermoCool RD Multi-electrode Ablation Catheter 28

In Pre-Clinical Development 29

Cardiosonic’s TIVUS System 29

Ablative Solutions’ PeriVascular Renal Denervation 29

Mercator MedSystems’ Micro-Infusion Catheter Technology 29

ApexNano Therapeutics’ Nanomagnetic Renal Denervation Technology 30

CryoMend/CryoMedix’s Cryoablation Technique 30

CyberHeart 31

Best Medical International’s Beta-Cath 3.5F Vascular Brachytherapy Catheter 31

Verve Medical’s Non-vascular Renal Denervation Procedure 32

COMPANY DIRECTORY 33

COMPANY PROFILES 35

Ablative Solutions 35

Apex Nano Therapeutics 36

Best Medical International 37

Boston Scientific 38

Vessix Vascular V2 Renal Denervation System 38

Cardiosonic 39

Covidien 40

OneShot Renal Denervation Device 40

Cryo Medix 41

Cyber Heart 42

Johnson & Johnson (Cordis ) 43

Renal Denervation with the Celsius Thermacool Ablation Catheter 43

RELIEF Clinical Study 44

Celsius ThermoCool RD Multi-electrode Ablation Catheter 44

Medtronic 45

Recent Key Events 45

Symplicity Renal Denervation System 46

Symplicity HTN Clinical Trials 46

In Development – Symplicity Spyral Multi-Electrode System 47

Mercator Med Systems 49

ReCor Medical 50

Recent Key Events 50

PARADISE Systems 50

Clinical Studies 50

Shanghai Angio Care Medical Technology 52

Sound Interventions 53

St Jude Medical 54

Recent Key Events 54

EnligHTN System 54

EnligHTN Clinical Studies 54

Second-Generation EnligHTN System 55

Verve Medical 56

APPENDICES 57

APPENDIX 1 – LIST OF ABBREVIATIONS 57

APPENDIX 2 – REPORT METHODOLOGY 58

Sources 58

Government and similar sources: 58

Renal denervation product manufacturers: 58

Professional organisations: 58

Medical Literature: 58

Market forecasts 59

List of Tables

Renal Denervation Market, 2011-2012 (US$ millions) 6

Current Renal Denervation Market Opportunity, Global and US 9

Summary: Market Drivers, Restraints and Opportunities 12

Major Renal Denervation Techniques: Benefits & Disadvantages 16

Recent Key Events 45

Recent Key Events 50

Recent Key Events 54

List of Charts

Fig.1: Renal Denervation Market Shares by Competitor, 2012 5

Fig.2: Renal Denervation Market by Region, 2012 6

Read the full report:

Challenges and Opportunities: in the Renal Denervation Market

http://www.reportbuyer.com/pharma_healthcare/diseases/challenges_opportunities_renal_denervation_market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

For more information:

Sarah Smith

Research Advisor at Reportbuyer.com

Email: query@reportbuyer.com

Tel: +44 208 816 85 48

Website: http://www.reportbuyer.com

For the original version on PRWeb visit: http://www.prweb.com/releases/2013/10/prweb11242579.htm


Source: prweb



comments powered by Disqus